We have shown that detectable ctDNA in patients with Stage III–IV NSCLC receiving first-line chemotherapy or targeted treatment was an indicator of poor prognosis using methylated homeobox A9 (HOXA9) as biomarker [37]. This evidence concerns the gene HOXA9 and non-small cell lung carcinoma.